Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18606473 | MRNA TREATMENT NANOPARTICLES | March 2024 | September 2024 | Allow | 6 | 2 | 0 | No | No |
| 18408431 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18342806 | P21 MRNA TARGET AREAS FOR SILENCING | June 2023 | March 2024 | Allow | 8 | 1 | 1 | No | No |
| 18316033 | SYNTHETIC SELF-AMPLIFYING MRNA MOLECULES WITH SECRETION ANTIGEN AND IMMUNOMODULATOR | May 2023 | May 2024 | Allow | 12 | 2 | 1 | Yes | No |
| 18181199 | RNAi Agents for Inhibiting Expression of DUX4, Compositions Thereof, And Methods of Use | March 2023 | October 2023 | Allow | 7 | 1 | 0 | No | No |
| 18160804 | METHODS FOR USING TRANSCRIPTION-DEPENDENT DIRECTED EVOLUTION OF AAV CAPSIDS | January 2023 | April 2024 | Allow | 14 | 2 | 1 | No | No |
| 18160796 | METHODS FOR USING TRANSCRIPTION-DEPENDENT DIRECTED EVOLUTION OF AAV CAPSIDS | January 2023 | April 2024 | Allow | 15 | 2 | 1 | No | No |
| 18078821 | SIGNAL BOOST CASCADE ASSAY | December 2022 | July 2023 | Allow | 8 | 1 | 2 | No | No |
| 18048390 | MRNA TREATMENT NANOPARTICLES | October 2022 | August 2023 | Allow | 10 | 1 | 0 | Yes | No |
| 17945842 | MULTI-CONJUGATE OF SIRNA AND PREPARING METHOD THEREOF | September 2022 | August 2023 | Allow | 11 | 2 | 0 | No | No |
| 17945739 | CANCER TREATMENT USING siRNA TO MODULATE EXPRESSION OF PRDM2/RIZ PROTEIN | September 2022 | February 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 17823586 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | August 2022 | November 2023 | Allow | 15 | 2 | 0 | No | No |
| 17823839 | METHOD OF STIMULATING PROLIFERATION OF A CELL | August 2022 | September 2024 | Abandon | 25 | 1 | 1 | No | No |
| 17850702 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF FORMULATING THE SAME | June 2022 | September 2022 | Allow | 3 | 1 | 0 | No | No |
| 17838984 | USE OF APTAMERS IN PROTEOMICS | June 2022 | November 2022 | Allow | 5 | 1 | 0 | Yes | No |
| 17826211 | COMPOSITIONS AND METHODS FOR INHIBITING MITOCHONDRIA AMIDOXIME REDUCING COMPONENT 1 (MARC1) EXPRESSION | May 2022 | February 2023 | Allow | 9 | 0 | 1 | No | No |
| 17804192 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | May 2022 | December 2022 | Allow | 7 | 1 | 0 | No | No |
| 17825376 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF C3 IN A CELL | May 2022 | April 2023 | Allow | 11 | 1 | 1 | No | No |
| 17747924 | DEFINED MULTI-CONJUGATES OLIGONUCLEOTIDES | May 2022 | August 2023 | Allow | 15 | 4 | 1 | Yes | No |
| 17740792 | MEDICAMENT USED FOR TREATING CHOLANGIOCARCINOMA WITH KRAS MUTATIONS | May 2022 | July 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17719580 | TREATMENT AND DETECTION OF INHERITED NEUROPATHIES AND ASSOCIATED DISORDERS | April 2022 | May 2024 | Allow | 25 | 3 | 1 | Yes | No |
| 17711137 | Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) Inhibitors | April 2022 | May 2023 | Allow | 13 | 2 | 1 | No | No |
| 17709705 | Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors | March 2022 | May 2023 | Allow | 13 | 2 | 1 | No | No |
| 17709275 | COMPOSITIONS AND METHODS FOR TREATING SARS-COV-2 INFECTION | March 2022 | June 2023 | Allow | 14 | 2 | 1 | No | No |
| 17709282 | METHODS FOR TREATING SARS-COV-2 INFECTION | March 2022 | January 2023 | Allow | 9 | 1 | 0 | No | No |
| 17671924 | LINKAGE MODIFIED OLIGOMERIC COMPOUNDS AND USES THEREOF | February 2022 | November 2022 | Allow | 9 | 1 | 0 | No | No |
| 17568757 | AGENT FOR USE IN THE TREATMENT OF GLIOMA | January 2022 | February 2024 | Allow | 26 | 0 | 0 | No | No |
| 17560008 | Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) Inhibitors | December 2021 | February 2024 | Allow | 26 | 2 | 0 | No | No |
| 17548241 | CIRCULAR RNA COMPOSITIONS AND METHODS | December 2021 | February 2023 | Allow | 14 | 2 | 1 | No | No |
| 17519546 | MODIFICATIONS OF MAMMALIAN CELLS USING ARTIFICIAL MICRO-RNA TO ALTER THEIR PROPERTIES AND THE COMPOSITIONS OF THEIR PRODUCTS | November 2021 | October 2022 | Allow | 11 | 2 | 1 | Yes | No |
| 17513047 | Noninvasive Medical Procedure for Destruction of Cancer and Precancerous Cells | October 2021 | August 2022 | Allow | 10 | 1 | 1 | Yes | No |
| 17508786 | LIPID NANOPARTICLE COMPOSITIONS AND METHODS OF FORMULATING THE SAME | October 2021 | June 2022 | Allow | 7 | 1 | 1 | Yes | No |
| 17503208 | CIRCULAR RNA COMPOSITIONS AND METHODS | October 2021 | January 2023 | Allow | 15 | 2 | 1 | No | No |
| 17500410 | RECOMBINANT VIRUS PRODUCTS AND METHODS FOR INDUCING DUX4 EXON SKIPPING | October 2021 | May 2024 | Allow | 31 | 1 | 0 | Yes | No |
| 17450008 | MATERIALS AND METHODS FOR DELIVERING NUCLEIC ACIDS TO COCHLEAR AND VESTIBULAR CELLS | October 2021 | May 2024 | Allow | 32 | 1 | 0 | No | No |
| 17466448 | Usb1 Directed Regulation Of Mirnas Related Hematopoietic Differentiation And Affected In Multiple Forms Of Leukemia | September 2021 | May 2024 | Allow | 32 | 2 | 1 | No | No |
| 17466454 | Dosage Form for Treating Severe Asthma | September 2021 | May 2024 | Allow | 32 | 1 | 0 | No | No |
| 17461876 | METHODS FOR IDENTIFICATION OF GENETIC MODIFIERS AND FOR TREATING NUCLEOTIDE REPEAT DISORDER | August 2021 | August 2023 | Abandon | 23 | 0 | 1 | No | No |
| 17404249 | Compositions of DNA Molecules, Methods of Making Therefor, and Methods of Use Thereof | August 2021 | August 2022 | Allow | 12 | 1 | 1 | No | No |
| 17392170 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | August 2021 | May 2022 | Allow | 9 | 1 | 0 | No | No |
| 17381024 | BASE-MODIFIED NUCLEOTIDES AS SUBSTRATES FOR TDT-BASED ENZYMATIC NUCLEIC ACID SYNTHESIS | July 2021 | January 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17417764 | Cell line with METTL3 gene knocked out, its construction method and interference vector | June 2021 | January 2022 | Allow | 7 | 0 | 0 | No | No |
| 17348125 | METHODS OF TREATING BREAST CANCER | June 2021 | July 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17413387 | METHODS FOR IMPROVING EXERCISE TOLERANCE IN MYALGIC ENCEPHALOMYELITIS PATIENTS | June 2021 | August 2023 | Allow | 26 | 1 | 0 | No | No |
| 17344920 | METHODS AND COMPOSITIONS FOR SYNTHESIS OF TWO-PHOTON CLEAVABLE PHOSPHORAMIDITE MOLECULES FOR OLIGONUCLEOTIDE CONJUGATION | June 2021 | December 2023 | Allow | 30 | 1 | 1 | No | No |
| 17337341 | METHODS FOR USING TRANSCRIPTION-DEPENDENT DIRECTED EVOLUTION OF AAV CAPSIDS | June 2021 | May 2022 | Allow | 12 | 1 | 1 | Yes | No |
| 17325883 | RNA POLYMERASE VARIANTS FOR CO-TRANSCRIPTIONAL CAPPING | May 2021 | April 2022 | Allow | 11 | 2 | 0 | No | No |
| 17307846 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | May 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17243503 | iRNA AGENTS WITH BIOCLEAVABLE TETHERS | April 2021 | July 2024 | Abandon | 39 | 1 | 0 | No | No |
| 17241920 | COMPOSITIONS CONTAINING NUCLEIC ACID NANOPARTICLES WITH MODULAR FUNCTIONALITY | April 2021 | February 2022 | Allow | 9 | 1 | 1 | No | No |
| 17225594 | RIG-I Agonists and Methods of Using Same | April 2021 | October 2022 | Abandon | 19 | 3 | 0 | No | No |
| 17222772 | USE OF APTAMERS IN PROTEOMICS | April 2021 | May 2024 | Allow | 38 | 1 | 0 | No | No |
| 17219000 | KIT, DEVICE, AND METHOD FOR DETECTING OVARIAN TUMOR | March 2021 | May 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17279206 | ANTISENSE RNA TARGETING PMP22 FOR THE TREATMENT OF CHARCOT-MARIE-TOOTH 1A DISEASE | March 2021 | November 2023 | Allow | 32 | 1 | 1 | No | No |
| 17202223 | CIRCULAR RNA COMPOSITIONS AND METHODS | March 2021 | November 2022 | Allow | 20 | 4 | 1 | Yes | No |
| 17188532 | COMPOUNDS AND THERAPEUTIC USES THEREOF | March 2021 | June 2024 | Abandon | 39 | 2 | 1 | Yes | No |
| 17181921 | COMPOSITIONS AND METHODS OF MODULATING HIF-2A TO IMPROVE MUSCLE GENERATION AND REPAIR | February 2021 | January 2024 | Allow | 35 | 0 | 1 | No | No |
| 17172002 | GNAQ Targeted dsRNA Compositions and Methods for Inhibiting Expression | February 2021 | February 2024 | Allow | 36 | 2 | 0 | No | No |
| 17170648 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | February 2021 | July 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17166985 | MICROSPHERE-BASED DELIVERY AND EX VIVO MANIPULATION OF DENDRITIC CELLS FOR AUTOIMMUNE THERAPIES | February 2021 | December 2023 | Abandon | 35 | 1 | 0 | No | No |
| 17157803 | METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF GLYCOLATE OXIDASE (HAO1) BY DOUBLE-STRANDED RNA | January 2021 | August 2023 | Allow | 31 | 1 | 0 | No | No |
| 17263090 | NUCLEIC ACIDS FOR INHIBITING EXPRESSION OF TMPRSS6 AND IRON CHELATORS | January 2021 | April 2024 | Allow | 38 | 2 | 1 | Yes | No |
| 17155743 | SYNP161, A PROMOTER FOR THE EXPRESSION OF GENES | January 2021 | August 2023 | Allow | 31 | 1 | 0 | No | No |
| 17147215 | COMPOUNDS AND METHODS FOR REDUCING SPDEF EXPRESSION | January 2021 | January 2022 | Abandon | 12 | 1 | 0 | No | No |
| 17145118 | FIDGETIN-LIKE 2 AS A TARGET TO ENHANCE WOUND HEALING | January 2021 | February 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17142192 | OLIGONUCLEOTIDE CONSTRUCTS AND USES THEREOF | January 2021 | November 2023 | Abandon | 35 | 0 | 1 | No | No |
| 17120973 | Modification of 3' Terminal Ends of Nucleic Acids by DNA Polymerase Theta | December 2020 | January 2024 | Allow | 37 | 1 | 0 | No | No |
| 17252126 | CIRCULATING MIRNAS AS BIOMARKERS FOR DIAGNOSIS OF MILD COGNITIVE IMPAIRMENT AND ALZHEIMERS DISEASE | December 2020 | March 2024 | Allow | 39 | 0 | 1 | No | No |
| 17103544 | MICRORNA PROFILING FOR DIAGNOSIS OF DYSPLASTIC NEVI AND MELANOMA | November 2020 | December 2023 | Allow | 36 | 1 | 0 | No | No |
| 17095059 | NOVEL PHARMACEUTICAL COMPOSITION COMPRISING PARTICLES AND METHODS OF MAKING SAME | November 2020 | September 2023 | Allow | 34 | 1 | 0 | No | No |
| 17091422 | COMPOSITIONS AND METHODS FOR SYNTHESIZING 5'-CAPPED RNAS | November 2020 | September 2023 | Allow | 34 | 1 | 0 | No | No |
| 17084995 | METHODS OF MAKING NOVEL PHARMACEUTICAL COMPOSITIONS | October 2020 | September 2023 | Allow | 35 | 1 | 0 | No | No |
| 17084217 | COMPOSITIONS COMPRISING EICOSAPENTAENOIC ACID AND MIPOMERSEN AND METHODS OF USE THEREOF | October 2020 | July 2023 | Allow | 33 | 1 | 0 | No | No |
| 17080333 | METHOD FOR MODULATING GENE EXPRESSION BY MODIFYING THE CPG CONTENT | October 2020 | July 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17080205 | Bicistronic AAV Vector for RNA Interference in ALS | October 2020 | September 2023 | Allow | 35 | 1 | 0 | No | No |
| 17075738 | METHOD OF TARGETING SENESCENT CELLS | October 2020 | October 2023 | Allow | 36 | 1 | 0 | No | No |
| 17027710 | Nucleic Acid Nanocapsules for Drug Delivery and Targeted Gene Knockdown | September 2020 | June 2023 | Allow | 33 | 1 | 0 | No | No |
| 17012787 | BRANCHED OLIGONUCLEOTIDES | September 2020 | September 2023 | Allow | 37 | 1 | 1 | No | No |
| 16978106 | NUCLEIC ACID MOLECULES AND METHODS OF USING THE SAME | September 2020 | September 2022 | Allow | 24 | 3 | 1 | No | No |
| 17006588 | DEVELOPMENT OF POLYLYSINE:EPIGALLOCATECHIN-3-O-GALLATE AND DSRNA POLYPLEXES FOR CONTROL OF MOSQUITOES | August 2020 | June 2023 | Allow | 34 | 2 | 0 | No | No |
| 17003254 | TRANSGENIC MICROALGAE AND USE THEREOF AS A FEED FOR DELIVERY OF INTERFERING RNA MOLECULES | August 2020 | October 2023 | Abandon | 38 | 1 | 1 | No | No |
| 17000215 | CORONAVIRUS RNA VACCINES | August 2020 | May 2021 | Allow | 9 | 1 | 1 | No | No |
| 16970845 | Targeting Cancer-Associated Long Non-Coding RNAs | August 2020 | January 2023 | Allow | 29 | 1 | 0 | No | No |
| 16995477 | NUCLEIC ACID COMPLEX, METHOD FOR FORMING NUCLEIC ACID HYBRIDIZATION, PHARMACEUTICAL COMPOSITION, NUCLEIC ACID PROBE, AND COMPLEMENTARY-STRAND NUCLEIC ACID COMPLEX | August 2020 | February 2024 | Allow | 42 | 1 | 1 | No | No |
| 16991192 | MEDICINE FOR TREATING DISORDERS OF GLUCOSE AND/OR LIPID METABOLISM AND A METHOD OF TREATING GLUCOSE AND/OR LIPID METABOLIC DISORDERS | August 2020 | March 2023 | Allow | 31 | 1 | 1 | No | No |
| 16968334 | Peptide Nucleic Acid Complex Having Endosomal Escape Capacity, And Use Thereof | August 2020 | March 2023 | Abandon | 32 | 1 | 1 | No | No |
| 16988395 | METHODS AND COMPOSITIONS FOR TREATING CANCER USING PEPTIDE NUCLEIC ACID-BASED AGENTS | August 2020 | August 2022 | Allow | 24 | 1 | 1 | No | No |
| 16983129 | USE OF SINGLE-STRANDED ANTISENSE OLIGONUCLEOTIDE IN PREVENTION OR TREATMENT OF GENETIC DISEASES INVOLVING A TRINUCLEOTIDE REPEAT EXPANSION | August 2020 | August 2023 | Abandon | 36 | 0 | 1 | No | No |
| 16938474 | DNA GRIDIRON COMPOSITIONS AND METHODS | July 2020 | April 2023 | Allow | 33 | 1 | 0 | No | No |
| 16937386 | METHODS FOR REDUCING C9ORF72 EXPRESSION | July 2020 | May 2023 | Abandon | 33 | 1 | 0 | No | No |
| 16962427 | NFAT BINDING POLYNUCLEOTIDES | July 2020 | March 2022 | Abandon | 20 | 1 | 1 | No | No |
| 16925545 | Aptamer Conjugates with N-Heterocyclic Carbene Metal Complexes for Targeted Drug Delivery | July 2020 | October 2023 | Allow | 39 | 2 | 0 | No | No |
| 16923408 | USE OF LEUCINE-ZIPPER PROTEIN FOR DIAGNOSIS OR TREATMENT OF FATTY LIVER | July 2020 | May 2022 | Allow | 22 | 1 | 0 | No | No |
| 16959944 | SERUM RESPONSE FACTOR REGENERATES SENESCENT CELLS | July 2020 | March 2024 | Allow | 44 | 2 | 0 | No | No |
| 16958371 | ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDES | June 2020 | August 2023 | Allow | 38 | 1 | 1 | No | No |
| 16907678 | Treatment Of Decreased Bone Mineral Density With Zinc And Ring Finger 3 (ZNRF3) Inhibitors | June 2020 | March 2023 | Allow | 33 | 1 | 1 | No | No |
| 16902717 | MATERIAL AND METHOD FOR COLORIMETRIC DETECTION OF SMALL-MOLECULE TARGETS | June 2020 | January 2021 | Allow | 7 | 1 | 0 | No | No |
| 16771323 | Modulation of Extracellular Vesicles with Electrical Stimulation | June 2020 | February 2024 | Allow | 44 | 3 | 1 | Yes | No |
| 16893253 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | June 2020 | February 2024 | Abandon | 44 | 1 | 1 | No | No |
| 16888344 | DECREASING LACTATE LEVEL AND INCREASING POLYPEPTIDE PRODUCTION BY DOWNREGULATING THE EXPRESSION OF LACTATE DEHYDROGENASE AND PYRUVATE DEHYDROGENASE KINASE | May 2020 | March 2021 | Allow | 9 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ZARA, JANE J.
With a 0.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ZARA, JANE J works in Art Unit 1635 and has examined 765 patent applications in our dataset. With an allowance rate of 52.8%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.
Examiner ZARA, JANE J's allowance rate of 52.8% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ZARA, JANE J receive 1.57 office actions before reaching final disposition. This places the examiner in the 41% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by ZARA, JANE J is 32 months. This places the examiner in the 30% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +21.4% benefit to allowance rate for applications examined by ZARA, JANE J. This interview benefit is in the 70% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 20.6% of applications are subsequently allowed. This success rate is in the 14% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 71.0% of cases where such amendments are filed. This entry rate is in the 91% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 66.7% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 50% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 75.0% of appeals filed. This is in the 59% percentile among all examiners. Of these withdrawals, 91.7% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 49.0% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 5.0% of allowed cases (in the 89% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 3.5% of allowed cases (in the 74% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.